PL2477649T3 - Szczepionka przeciwko biegunce powodowanej przez cholerę i enterotoksynogenną e. coli (etec) - Google Patents

Szczepionka przeciwko biegunce powodowanej przez cholerę i enterotoksynogenną e. coli (etec)

Info

Publication number
PL2477649T3
PL2477649T3 PL10817520T PL10817520T PL2477649T3 PL 2477649 T3 PL2477649 T3 PL 2477649T3 PL 10817520 T PL10817520 T PL 10817520T PL 10817520 T PL10817520 T PL 10817520T PL 2477649 T3 PL2477649 T3 PL 2477649T3
Authority
PL
Poland
Prior art keywords
etec
enterotoxigenic
diarrhea
coli
vaccine against
Prior art date
Application number
PL10817520T
Other languages
English (en)
Inventor
Jan Holmgren
Michael Lebens
Original Assignee
Msd Wellcome Trust Hilleman Laboratories Pvt Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Msd Wellcome Trust Hilleman Laboratories Pvt Ltd. filed Critical Msd Wellcome Trust Hilleman Laboratories Pvt Ltd.
Publication of PL2477649T3 publication Critical patent/PL2477649T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/107Vibrio
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/002Protozoa antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
PL10817520T 2009-09-16 2010-09-16 Szczepionka przeciwko biegunce powodowanej przez cholerę i enterotoksynogenną e. coli (etec) PL2477649T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27235109P 2009-09-16 2009-09-16

Publications (1)

Publication Number Publication Date
PL2477649T3 true PL2477649T3 (pl) 2017-06-30

Family

ID=43758898

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10817520T PL2477649T3 (pl) 2009-09-16 2010-09-16 Szczepionka przeciwko biegunce powodowanej przez cholerę i enterotoksynogenną e. coli (etec)

Country Status (15)

Country Link
US (1) US9511133B2 (pl)
EP (1) EP2477649B1 (pl)
JP (2) JP2013505017A (pl)
KR (1) KR101722802B1 (pl)
CN (1) CN102630166B (pl)
AU (1) AU2010296065B2 (pl)
CA (1) CA2774335C (pl)
DK (1) DK2477649T3 (pl)
ES (1) ES2616912T3 (pl)
HU (1) HUE031957T2 (pl)
IN (1) IN2012DN02860A (pl)
PL (1) PL2477649T3 (pl)
PT (1) PT2477649T (pl)
WO (1) WO2011034495A1 (pl)
ZA (1) ZA201202710B (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
CN102824632A (zh) * 2012-09-12 2012-12-19 北京民海生物科技有限公司 霍乱弧菌o1群多糖结合疫苗、其制备方法及应用
RU2535122C1 (ru) * 2013-11-06 2014-12-10 Федеральное казенное учреждение здравоохранения "Российский научно-исследовательский противочумный институт "Микроб" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека ("РосНИПЧИ "Микроб") Способ получения холерогена-анатоксина
RU2563620C2 (ru) * 2014-08-05 2015-09-20 Федеральное казенное учреждение здравоохранения "Российский научно-исследовательский противочумный институт "Микроб" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека ("РосНИПЧИ "Микроб") Способ получения таблетированной формы холерной бивалентной химической вакцины
EP3390646A4 (en) * 2015-12-14 2019-10-30 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. NOVEL METHOD FOR THE PRODUCTION OF CLEANED RECOMBINANT CHOLERATOXIN B (RCTB) AND FORMULATION THEREOF
JP6820565B2 (ja) * 2016-04-27 2021-01-27 国立大学法人大阪大学 病原性細菌の定着を阻害するペプチド及びそれを含む定着阻害剤
US20210085775A1 (en) 2017-12-15 2021-03-25 Valneva Sweden Ab Methods and composition for preventing and/or treating cancer
WO2021005623A1 (en) * 2019-07-08 2021-01-14 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. A vaccine formulation for protection against enterotoxigenic e. coli (etec) and cholera
WO2021105061A1 (en) 2019-11-25 2021-06-03 Gotovax Ab Whole cell vaccines and methods of production thereof
EP4058056A1 (en) 2020-10-07 2022-09-21 Valneva Sweden AB Cholera vaccine formulation
WO2022117823A1 (en) 2020-12-04 2022-06-09 Valneva Se Methods and compositions for preventing and/or treating autoimmune diseases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5882653A (en) * 1983-03-04 1999-03-16 The University Of Maryland System Vibrio cholerae 01 (CVD111) and non-01 (CVD112 and CVD112RM) serogroup vaccine strains, methods of making same and products thereof
US5330753A (en) * 1987-04-29 1994-07-19 President And Fellows Of Harvard College Cholera vaccines
CA2139655C (en) * 1992-07-06 2008-05-13 John J. Mekalanos Deletion mutants as vaccines for cholera
US6203799B1 (en) * 1993-07-01 2001-03-20 Presidents And Fellows Of Harvard College Vibrio cholerae mutants which are soft-agar penetration defective and lack a functional CtxA subunit
JP3098401B2 (ja) 1995-07-12 2000-10-16 株式会社エルティーティー研究所 経鼻投与用製剤
WO2000067784A1 (en) * 1999-05-10 2000-11-16 University Of Maryland, Baltimore Bacteriophage isolated from bacterial genomes and extrachromosomal elements and methods of use thereof
US7270961B2 (en) * 2002-04-16 2007-09-18 Hui Sunny Chang In vitro assay for quantitating secreted antibodies in lymphocyte supernatant for evaluation of vaccine or antigen induced specific antibody secretion from ex vivo circulating antibody-secreting lymphocytes
US20060171966A1 (en) * 2002-08-30 2006-08-03 Centre For Health And Population Research Variants of vibrio cholerae 01 biotype e1 tor with attributes of classical biotype
CU23334A1 (es) * 2003-03-20 2008-12-24 Inst Finlay Vacuna de vibrio cholerae inactivada en tabletas
US20060099229A1 (en) * 2004-11-05 2006-05-11 Universiti Sains Malaysia Vibrio cholerae strains VCUSM1 and VCUSM4, method of producing same, and vaccine derivatives thereof
EP1543836A1 (en) * 2003-12-17 2005-06-22 Berna Biotech AG Recombinant Vibrio cholerae strain and vaccine comprising said strain
WO2009049013A2 (en) * 2007-10-09 2009-04-16 Tufts University Cholera vaccines

Also Published As

Publication number Publication date
WO2011034495A1 (en) 2011-03-24
CN102630166A (zh) 2012-08-08
ZA201202710B (en) 2015-12-23
CA2774335C (en) 2016-10-18
HUE031957T2 (en) 2017-09-28
ES2616912T3 (es) 2017-06-14
JP6178384B2 (ja) 2017-08-09
KR20120081600A (ko) 2012-07-19
US20120276146A1 (en) 2012-11-01
US9511133B2 (en) 2016-12-06
IN2012DN02860A (pl) 2015-06-19
JP2016074695A (ja) 2016-05-12
AU2010296065B2 (en) 2015-05-21
PT2477649T (pt) 2017-03-01
CA2774335A1 (en) 2011-03-24
JP2013505017A (ja) 2013-02-14
AU2010296065A1 (en) 2012-05-10
DK2477649T3 (en) 2017-03-06
EP2477649A1 (en) 2012-07-25
CN102630166B (zh) 2015-08-05
EP2477649A4 (en) 2013-01-30
KR101722802B1 (ko) 2017-04-03
EP2477649B1 (en) 2016-11-23

Similar Documents

Publication Publication Date Title
PT2477649T (pt) Vacina contra a diarreia devida a e. coli enterotoxigênica (etec) e a cólera
IL207482A0 (en) Devices, methods and sysems for control of heliostats
EP2300553A4 (en) HEAT TRANSFER SYSTEM, LIQUID AND METHOD
AP2011005776A0 (en) Pharmaceutical composition comprising linagliptin and optionally a SGLT2 inhibitor, and uses thereof.
AP2011006035A0 (en) Fluid treatment apparatus.
EP2436961A4 (en) Valve, fluid apparatus and fluid supply apparatus
PL2331651T3 (pl) Czynnik do przenoszenia ciepła
IL200475A0 (en) Mitral valve system
EP2249758A4 (en) THERMAL TRANSFER DEVICE FOR PATIENT
EP2274044A4 (en) FLUID TRANSFER ASSEMBLIES AND ASSOCIATED METHODS
EP2111173A4 (en) TREATMENT SYSTEM AND TREATMENT DEVICE
EP2165302A4 (en) Card-free collection systems and methods
EP2419071A4 (en) APPARATUS FOR LIQUID TRANSMISSION
AP2012006064A0 (en) Compounds and methods for treating influenza.
SG10201405839XA (en) Fluid transfer device and system
EG25169A (en) Cementing valve.
EP2432012A4 (en) HEAT EXCHANGER, SEMICONDUCTOR DEVICE, METHOD FOR MANUFACTURING THE HEAT EXCHANGER, AND METHOD FOR MANUFACTURING THE SEMICONDUCTOR DEVICE
EP2447229A4 (en) GLASS SHIELD AGAINST THERMAL RAYS, AND LAMINATED SHIELDING GLASS AGAINST THERMAL RAYS
PL2700411T3 (pl) Probiotyki, wydzielnicze IgA a zakażenie
BRPI1014852A2 (pt) acoplamento tipo de crimpagem, ferramenta de crimpagem e método de crimpagem.
HK1132202A1 (en) Uv treatment reactor
ZA201002445B (en) Hiv preventive vaccine based on hiv specific antibodies
ZA201106359B (en) Flue gas treatment system and the method using amonia solution
GB2456401A9 (en) Ion handling devices.
EP2491946A4 (en) ADJUVANT FOR VACCINES, VACCINES COMPRISING SAME, AND USES THEREOF